Register
Login:
Share:
Email Facebook Twitter

PHARMA: Heat Biologics - a 'potentially transformative' lung cancer treatment, Phase II data Q3 2018 Watch here

Looking for big risk, big reward investing? See our exclusive Pharma video series from 'Biotech and Money'


ShareCast News


Amphion partner Polarean Imaging valued at $19m ahead of planned IPO

Fri, 10th Nov 2017 15:16


(ShareCast News) - Medical, life science and technology business Amphion Innovations updated the market on its partner company Polarean Imaging, in which Amphion currently has an interest of around 26%, on Friday.

The AIM-traded firm described Polarean as a revenue generating, late clinical stage medical company operating in the high resolution imaging market.

It develops equipment that enables existing MRI systems to achieve an improved level of pulmonary functional imaging, and specialises in the use of polarised 129Xenon gas as an imaging agent to visualise ventilation and gas exchange in the lung.

"Polarean's technology could therefore enable the early stage diagnosis of pulmonary diseases, including chronic obstructive pulmonary disease (COPD)," the Amphion board said in its statement.

"Polarean has clear guidance from the US Food and Drug Administration to commence a pivotal Phase III trial on its flagship drug-device platform."

Further to the Amphion's announcement on 31 May, Polarean's proposed IPO and admission to AIM was progressing.

As such, Northland Capital Partners - who are acting as Polarean's nominated adviser and broker - has today published a research report on Polarean ahead of an investor roadshow.

"The Northland research report anticipates a pre new money valuation of Polarean of circa $29m, compared with the valuation of circa $22m on a post new money basis which was implied by the pre-IPO fundraise of $2m, completed by Polarean in May, and the further grant of options in Polarean," Amphion's board said in its statement.

"The implied valuation in the Northland Research Report is based, amongst other things, on current market conditions and there can be no assurance that this valuation will be achieved at the conclusion of Polarean's IPO roadshow.

"Furthermore, there can be no assurance as to whether or when the IPO of Polarean may be completed, or as to the actual size or final terms of the IPO."





Back to ShareCast News


Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk




Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.